



## EmphyCorp Latest Publication in the European Journal of Respiratory Medicine “Reduces Lung Inflammation and Fibrosis”

**Flemington, NJ – January 16, 2024** - EmphyCorp Inc. [www.EmphyCorp.com](http://www.EmphyCorp.com), a private corporation, with several late stage drugs, specializes in Rx Non-Steroidal Nasal and Oral Spray Technology for the treatment of Interstitial Lung Disease (orphan drug designation), Respiratory Diseases, Allergic Rhinitis, Long COVID, Flu, and COVID-19.

**Latest Publication: European Journal of Respiratory Medicine Peer Review of Inhaled Sodium Pyruvate Reduces Lung Inflammation and Fibrosis in a Bleomycin Rat Model with N115 was published on January 9, 2024.** [EmphyCorp-EJRP-Peer-Review-Inhaled-Sodium-Pyruvate-Reduces-Lung-Inflammation-and-Fibrosis-in-a-Bleomycin-Rat-Model-010924.pdf](https://www.EmphyCorp.com/EJRP-Peer-Review-Inhaled-Sodium-Pyruvate-Reduces-Lung-Inflammation-and-Fibrosis-in-a-Bleomycin-Rat-Model-010924.pdf)

The Patented N115 Technology Platform has demonstrated efficacy, with no known side effects, in 23 human clinical studies for all lung and sinus diseases tested including COPD, Interstitial Lung Disease (Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis), Long COVID, Allergic Rhinitis, Chronic Rhinitis, and Sinusitis. Our Drug Pipeline also includes treatments for Pulmonary Hypertension.

In each Clinical Trial, N115 produced statistically significant increases in all lung functions with the reduction in nasal and respiratory inflammation, a reduction in oxygen radicals, congestion, coughing, fatigue, and a reduction of inflammatory cytokines including IL-6, a cause of the cytokine storm in COVID-19 patients. N115 also increases the synthesis of nasal nitric oxide, a natural defence molecule that kills invading bacteria, fungi, and viruses to prevent and reduce the severity of infections.

**EmphyCorp/Cellular Sciences is now treating Patients in a US Phase III Clinical Trial with our Rx N115 Nonsteroidal Nasal Spray in Idiopathic Pulmonary Fibrosis (IPF) for Coughing and Improved Lung Function (secondary medical endpoint).**

This IPF Phase III Clinical Trial is listed on [www.ClinicalTrials.Gov](http://www.ClinicalTrials.Gov) under Cellular Sciences (Listed as Sponsor): <https://www.clinicaltrials.gov/search?spons=Cellular%20Sciences,%20inc>.

**EmphyCorp has 5 Peer Reviewed articles and 8 Drug Patents including (3) new Drug Patents for the treatment of:**

- Apoptosis of Myofibroblasts (Slowing/stopping fibrosis/scarring of the lungs)
- Hypoxemia (low oxygen) & Dyspnea (shortness of breath) and Coughing
- Coronavirus/Influenza

Given our success in treating Pulmonary Fibrosis patients and the other respiratory diseases, our research focused on treating the symptoms in COVID-19 infected patients and in Long COVID patients including hypoxemia (low SaO<sub>2</sub>), dyspnea (shortness of breath), fatigue, coughing/sneezing, trouble breathing, body aches, headaches, and Pulmonary Fibrosis.

**Phase III Clinical Trials have been successfully completed for Patients with Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis (IPF)**

- The data showed that coughing episodes per day were significantly reduced in all patients on day 8 by 30% (p=0.007) and continued to decrease on day 14 by 55% (p=0.0001) and on the 22<sup>nd</sup> day of the trial, coughing decreased by 59% (p=0.0001).
- This correlated with a significant (p=0.010) improvement in nasal irritation/erythema with most patients being free of irritation by day 22 (p<0.001); and a significant (p=0.010) increase in the group average expelled NO by day 8. A significant (p=0.010) improvement in lung function (breathing) was observed in all patients with IPF by day 1, increasing to p=0.0005 by day 22 compared to their baseline therapies, determined by changes in FVC, FEV<sub>1</sub>, PEF, and FEV<sub>1</sub>/FVC ratios.
- The improved FEV<sub>1</sub>/FVC ratio from 52% to 86% was clinically significant and indicated that current therapies in use are inadequate to treat patient with IPF.

**EmphyCorp N115 Nasal Sprays have also been used to treat over 3 million patients globally in 200 hospitals, with no adverse events.**

Dr. Alain Martin (CEO) created the EmphyCorp Patented Nasal and Oral Sprays, as well as Advanced Neosporin, Advanced Lubriderm, Early Pregnancy Test (EPT), Cool Mint Listerine, plus discovering the use of Rx Rezulin Drug for Type II Diabetes earlier in his career at Warner Lambert (Pfizer acquisition). He also created patented OTC and Rx products including next generation triple antibiotic, skincare, drug free post laser aftercare lotion with a cooling gel for pain, patented pet anxiety product (OTC or Rx) with no side effects for our sister company North Cell Pharmaceutical [www.NorthCellPharma.com](http://www.NorthCellPharma.com).

An Up-to-date Rx N115 Nasal Spray and Oral Spray Drug Pipeline, Peer Reviews, and Press Releases can be found on the EmphyCorp website [www.EmphyCorp.com](http://www.EmphyCorp.com).

**Please contact Robert Millar for more information and Partnership interest at 973-586-4421 or [EmphyCorp@optonline.net](mailto:EmphyCorp@optonline.net).**

---